Mumps Virus Vaccines for Mumps

Not currently recruiting at 2 trial locations

Overseen By Henry Radziewicz, MD

Age: 18 - 65

Sex: Any

Trial Phase: Phase 1

Sponsor: CyanVac LLC

Must not be taking: Immunosuppressants, Immunotherapy

Disqualifiers: Mumps vaccination, COVID-19, Influenza, others

Compensation: Varies

Number of Visits: 7

Duration: 1 day

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two new mumps vaccines, CVM150 and CVM26, to determine their safety and ability to help the body defend against mumps. Mumps is a contagious viral infection that causes swelling of the glands around the neck. Individuals who have previously received two doses of the mumps vaccine as children and are generally healthy are suitable for this study. Participants will receive either one of the new vaccines or a placebo, a harmless substance with no effect. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive these new vaccines.

Will I have to stop taking my current medications?

The trial does not require you to stop taking your current medications as long as they are stable and do not pose additional risks or interfere with the trial. However, any changes in medication should not be due to a worsening condition, and you should discuss your specific situation with the trial investigator.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that live weakened mumps vaccines, such as CVM150 and CVM26, are generally safe. In past studies, only about 2.13% of participants experienced side effects, most of which were mild and resolved quickly. This suggests that both CVM150 and CVM26 are likely well-tolerated by most people. However, as this trial is in its early stages and primarily focuses on safety, additional information may be needed to confirm these early findings. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these mumps vaccines, CVM150 and CVM26, because they offer unique approaches compared to current options like the MMR (measles, mumps, rubella) vaccine. CVM150 is distinct because it uses a live PIV5-based vaccine that expresses specific proteins from the Iowa strain of the mumps virus, potentially enhancing immune response. On the other hand, CVM26 is genetically edited to remove certain viral protein expressions, which might improve safety and efficacy. These innovative approaches could lead to better protection against mumps, sparking excitement in the scientific community.

What evidence suggests that this trial's treatments could be effective for mumps?

Studies have shown that traditional mumps vaccines, such as the MMR (measles-mumps-rubella) vaccine, are about 88% effective after two doses. However, this protection typically decreases around 27 years after vaccination. This trial tests CVM150 and CVM26, new experimental vaccines, to determine if they offer strong protection against mumps. CVM150 uses a virus-based method to create proteins that trigger an immune response, while CVM26 is a live, weakened version of the virus with some proteins removed. These vaccines aim to help the body's immune system recognize and fight the mumps virus more effectively. Early research suggests that these new vaccines could provide protection similar to or better than current vaccines. ^{1 6 7 8 9}

Who Is on the Research Team?

Hong Jin

Principal Investigator

CyanVac LLC

Are You a Good Fit for This Trial?

This trial is for up to 60 healthy adults. Specific eligibility criteria are not provided, but typically participants should have no underlying health conditions that could affect the outcome of the vaccine study.

Inclusion Criteria

I am using or willing to use birth control or practice abstinence.

Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, and other trial procedures

Determined by medical history, complete physical examination, and clinical judgement of the investigator to be in good state of health

Exclusion Criteria

I have not had COVID-19 in the last 30 days.

I have previously received a PIV5-based or investigational mumps vaccine.

I have been vaccinated for mumps in the last 10 years.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single intranasal dose of CVM150, CVM26, or placebo on Day 1

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and immunogenicity, including local and systemic reactogenicity, immune response, and adverse events

6 months

Approximately 6-7 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• CVM150
• CVM26

Trial Overview

The trial is testing two intranasal mumps virus vaccines: CVM150 and CVM26, against a placebo. The goal is to assess their safety and how well they stimulate the body's immune response (immunogenicity).

How Is the Trial Designed?

Group I: CVM26 Experimental Treatment 1 Intervention

CVM26: A live, attenuated MuV vaccine based on Iowa strain genetically edited to remove the V and SH protein expression. Formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.

Group II: CVM150 Experimental Treatment 1 Intervention

CVM150: Live PIV5-based MuV vaccine expressing the MuV (Iowa strain/2006) F and HN proteins formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.

Group III: Placebo Placebo Group 1 Intervention

Placebo: 0.9% normal sterile saline (purchased commercially).

Who Is Running the Clinical Trial?

CyanVac LLC

Lead Sponsor

Trials

3

Recruited

10,300+

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06967181

NCT06967181 | A Phase 1 Trial of Intranasal Mumps Virus ...

This is a randomized, blinded, placebo-controlled, phase 1 clinical trial to evaluate the safety and immunogenicity of CVM150 and CVM26 in healthy adults ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC5899613/

Vaccine waning and mumps re-emergence in the United States

We estimated that vaccine-derived immune protection against mumps wanes on average 27 (95% confidence interval: 16 to 51) years post-vaccination.

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12452436/

Incremental effectiveness of the second dose of mumps ...

Subgroup analyses revealed a higher vaccine effectiveness (IVE) in children with a vaccination interval of <1 year (32.67%; 95% CI: 8.44 to ...

4.

health.state.mn.us

health.state.mn.us/diseases/mumps/muminfographic.pdf

How effective is the Mumps vaccine?

Mumps vaccine is effective. Two doses of the measles-mumps-rubella. (MMR) vaccine will be effective against mumps in about 88% of people vaccinated.

5.

wwwnc.cdc.gov

wwwnc.cdc.gov/eid/article/13/1/06-0649_article

Vaccine Effectiveness Estimates, 2004–2005 Mumps ...

The effectiveness of 1 dose declined from 96% (95% CI 81%–99%) in 2-year-olds to 66% (95% CI 30%–83%) in 11- to 12-year-olds, and the ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10513284/

Safety analysis of a live attenuated mumps vaccine in ...

A total of 214 subjects reported adverse reactions with an incidence of 2.13% (214/10057). Most adverse reactions were grade 1, and the ...

7.

withpower.com

withpower.com/trial/phase-1-mumps-4-2025-dac90

Mumps Virus Vaccines for Mumps · Info for Participants

The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants. Show more ...

8.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC4896512/

Safety and immunogenicity of a live attenuated mumps ...

Conclusions: The F-genotype attenuated mumps vaccine evaluated in this clinical trial was demonstrated to be safe and have effective immunogenicity vs. control.

9.

ichgcp.net

ichgcp.net/clinical-trials-registry/536983-a-phase-1-trial-of-intranasal-mumps-virus-vaccines-in-healthy-adults

Phase 1 Study of Intranasal Mumps Vaccines CVM150 and ...

Phase 1 clinical trial evaluating safety and immune responses to novel intranasal mumps vaccines CVM150 and CVM26 in healthy adults ...